Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity

Inclusion Criteria: * Willing and able to give written informed consent. * Histologic diagnosis of melanoma with in transit metastasis Stage IIIB, IIIC, or IV * Required values for initial laboratory tests: * WBC ≥ 2000/uL * ANC ≥ 1000/uL * Platelets ≥ 50 x 103/uL * Hemoglobin ≥ 8 g/dL * Creatinine ≤ 3.0 x ULN * AST/ALT ≤ 2.5 x ULN * Bilirubin ≤ 3.0 x ULN, (except patients with Gilbert's Syndrome, who must have a total bilirubin less than 3.0 mg/dL) * No active or chronic infection with HIV, Hepatitis B, or Hepatitis C. * Karnofsky performance status ≥60 * Men and women, ≥ 18 years of age. Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 8 weeks after the last dose of investigational product, in such a manner that the risk of pregnancy is minimized. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not post-menopausal. Post-menopause is defined as: * Amenorrhea ≥ 12 consecutive months without another cause, or * For women with irregular menstrual periods and taking hormone replacement therapy (HRT), a documented serum follicle stimulating hormone (FSH) level ≥ 35 mIU/mL. * Women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an …